T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Gulfport Energy Corp
GPOR
$3.01B
| $26M | ﹤0.01% |
124,956
+1,350
| +1% | +$269K |
|
1002
Globant
GLOB
$1.77B
| $25.9M | ﹤0.01% |
395,721
-332,699
| -46% | -$20.9M |
|
1003
Dianthus Therapeutics
DNTH
$6.13B
| $25.4M | ﹤0.01% |
616,033
+399,898
| +185% | +$15.5M |
|
1004
International Flavors & Fragrances
IFF
$21.4B
| $25.3M | ﹤0.01% |
375,583
-1,281
| -0.3% | -$82.9K |
|
1005
Allegion
ALLE
$14.2B
| $25.3M | ﹤0.01% |
158,776
+14,086
| +10% | +$2.35M |
|
|
HTFL
1006
Heartflow Inc
HTFL
$2.67B
| $25.2M | ﹤0.01% |
863,271
-351,725
| -29% | -$11.3M |
|
1007
Genuine Parts
GPC
$18.5B
| $25.1M | ﹤0.01% |
204,255
-1,425
| -0.7% | -$184K |
|
1008
Addus HomeCare
ADUS
$2.2B
| $24.9M | ﹤0.01% |
231,882
+1,723
| +0.7% | +$198K |
|
1009
Vanguard S&P 500 ETF
VOO
$1.04T
| $24.7M | ﹤0.01% |
39,452
| – | – |
|
1010
Xencor
XNCR
$1.72B
| $24.5M | ﹤0.01% |
1,601,762
-91,530
| -5% | -$1.37M |
|
1011
Shift4
FOUR
$3.47B
| $24.5M | ﹤0.01% |
388,352
+8,138
| +2% | +$575K |
|
1012
Nuvation Bio
NUVB
$2.25B
| $24.3M | ﹤0.01% |
2,708,553
+2,424,109
| +852% | +$15M |
|
1013
Aptiv
APTV
$10.2B
| $24.2M | ﹤0.01% |
317,622
+2,540
| +0.8% | +$204K |
|
1014
Texas Pacific Land
TPL
$23.6B
| $24.1M | ﹤0.01% |
83,946
+1,059
| +1% | +$323K |
|
|
SEZL
1015
Sezzle
SEZL
$4.37B
| $24M | ﹤0.01% |
378,185
+257,659
| +214% | +$17.6M |
|
1016
Qualys
QLYS
$6.47B
| $23.9M | ﹤0.01% |
179,556
+1,782
| +1% | +$245K |
|
1017
IES Holdings
IESC
$15.3B
| $23.7M | ﹤0.01% |
60,821
+1,299
| +2% | +$522K |
|
1018
Hims & Hers Health
HIMS
$6.71B
| $23.6M | ﹤0.01% |
726,487
-2,341,642
| -76% | -$100M |
|
1019
Mid-America Apartment Communities
MAA
$15.4B
| $23.6M | ﹤0.01% |
169,699
-888
| -0.5% | -$118K |
|
1020
LeMaitre Vascular
LMAT
$1.87B
| $23.5M | ﹤0.01% |
290,069
-238,310
| -45% | -$20.5M |
|
1021
Elastic
ESTC
$8.94B
| $23.5M | ﹤0.01% |
311,409
+22,344
| +8% | +$1.82M |
|
1022
Albemarle
ALB
$15.1B
| $23.5M | ﹤0.01% |
165,944
-1,038
| -0.6% | -$118K |
|
1023
Doximity
DOCS
$4.74B
| $23.5M | ﹤0.01% |
529,923
-88,150
| -14% | -$4.95M |
|
|
TLNCU
1024
Talon Capital Corp Units
TLNCU
| $23.2M | ﹤0.01% |
2,256,778
-33
| -0% | -$339 |
|
1025
Bio-Rad Laboratories Class A
BIO
$9.68B
| $23.1M | ﹤0.01% |
76,271
+794
| +1% | +$248K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.